mardi 22 septembre 2020


Wednesday, August 24th 2016 at 6:40am UTC

STOCKHOLM–(BUSINESS WIRE)– Cantargia AB (“Cantargia”) interim report for January – June 2016 is
available on the company website (www.cantargia.com/Investors/Reports).

Significant events in the second quarter

· The exercise period for warrants of series TO 1 and TO 3 began on 23
March 2016 and ended on 13 April 2016. In total, 4,127,260 warrants of
both series were exercised, representing around 83.5 per cent of the
number of warrants issued. Through the warrants Cantargia raised
approximately SEK 31.4 million before issue costs.

· During the period the Company gave investor presentations at the
international BioEquity conference in Copenhagen on 10 May 2016 and at
the Småbolagsdagen small cap investor event at the Sheraton Stockholm
Hotel on 13 June 2016.

· The annual report for the financial year 2015 was published on 29
April 2016. The company held its Annual General Meeting on 25 May 2016
and published a report on the AGM the following day. The annual report
and AGM report are available for download on the company’s website, www.cantargia.com.

· Cantargia received a Notice of Allowance from the US Patent Office for
IL1RAP as target molecule for antibody-based treatment in acute
lymphoblastic leukemia followed by a Notice of Allowance for IL1RAP as
target molecule for antibody-based treatment in solid tumours from the
same patent office. The company also received formal approval in Japan
of a patent for solid tumours.

· The company announced that its CAN04 product candidate has been shown
to have a high level safety in high doses – repeated treatment with up
to 100 mg/kg. During the period Cantargia also decided that the company
will conduct further process development studies to establish a strong
foundation for long-term production and that the start of the GLP
toxicity study will therefore be postponed until autumn 2016.
Consequently, the start of clinical studies will also be postponed until
the end of the first quarter of 2017.

· A third party filed an opposition to Cantargia’s patent in Europe for
IL1RAP as a target molecule for antibody treatment and leukemia
diagnostics. Cantargia will be working with its patent agents and the
European Patent Office to conduct the process in a professional and
correct manner.

Significant events after the end of the period

· In July Cantargia announced that the US Patent Office had approved the
company’s application for IL1RAP as target molecule for antibody-based
treatment of solid tumours.

· In August Cantargia announced that the company’s former CEO, Agneta
Svedberg, has exercised 1,250 warrants of series 2011/2016. The exercise
of the warrants will raise SEK 250,212.50 for Cantargia.

Financial information

First half (1 Jan 2016 – 30 Jun 2016)

· Other operating revenue was kSEK 0 (0).

· Earnings after financial items were kSEK -16,023 (-9,059).

· Earnings per share were approximately SEK -0.91 (-0.68).

· The equity/assets ratio was around 87 (89) per cent compared with the
beginning of the year.

Second quarter (1 Apr 2016 – 30 Jun 2016)

· Other operating revenue was kSEK 0 (0).

· Earnings after financial items were kSEK -7,926 (-5,432).

· Earnings per share were approximately SEK -0.45 (-0.41).

Definitions

· Earnings per share: Profit for the period divided by 17,633,134 shares
as at 30 June 2016.

· Equity/assets ratio: Equity divided by total capital.

· Unless otherwise indicated, figures in parentheses refer the same
period in the previous year.

This constitutes information that Cantargia is required to publish under
the EU’s Market Abuse Regulation. The information was submitted for
publication through the above contact person at 8:30 (CEST) on August
24, 2016.

This information was brought to you by Cision http://news.cision.com

Contacts

Cantargia AB
Göran Forsberg, CEO
Telephone: +46 (0)46 275 62 60
E-mail:
goran.forsberg@cantargia.com
Certified
Adviser: Sedermera Fondkommission

Source: Cantargia AB

Étiquettes : , , , , , , ,